- MSN and Aurobindo agreed to be blocked from making copies until patents have expired or have been invalidated, “absent a license or other authorization” by Allergan, according to
stipulationsand ordersapproved Tuesday in federal court in Newark, New Jersey
- Bench trial had been set to begin Sept. 7
- AbbVie sent confidential letter to judge that day; it remains sealed
- Allergan filed complaints starting in October 2017; MSN and Aurobindo were only remaining ...
Sept. 15, 2021, 2:58 PM